INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2).

Melissa Bersanelli; Diana Giannarelli; Ugo De Giorgi; Sandro Pignata; Massimo Di Maio; Alberto Clemente; Elena Verzoni; Raffaele Giusti; Marilena Di Napoli; Giuseppe Aprile; Paola Ermacora; Annamaria Catino; Vieri Scotti; Francesca Mazzoni; Pamela Francesca Guglielmini; Antonello Veccia; Marco Maruzzo; Ernesto Rossi; Francesco Grossi; Chiara Casadei; Corrado Ficorella; Vincenzo Montesarchio; Francesco Verderame; Mimma Rizzo; Giorgia Guaitoli; Lucia Fratino; Caterina Accettura; Manlio Mencoboni; Fable Zustovich; Cinzia Baldessari; Saverio Cinieri; Andrea Camerini; Letizia Laera; Mariella Sorarù; Paolo Andrea Zucali; Valentina Guadalupi; Francesco Leonardi; Marcello Tiseo; Michele Tognetto; Francesco Di Costanzo; Carmine Pinto; Giorgia Negrini; Antonio Russo; Maria R. Migliorino; Marco Filetti; Sebastiano Buti

doi:10.1136/jitc-2021-002619

INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2).

Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Alberto Clemente, Elena Verzoni, Raffaele Giusti, Marilena Di Napoli, Giuseppe Aprile, Paola Ermacora, Annamaria Catino, Vieri Scotti, Francesca Mazzoni, Pamela Francesca Guglielmini, Antonello Veccia, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara CasadeiCorrado Ficorella, Vincenzo Montesarchio, Francesco Verderame, Mimma Rizzo, Giorgia Guaitoli, Lucia Fratino, Caterina Accettura, Manlio Mencoboni, Fable Zustovich, Cinzia Baldessari, Saverio Cinieri, Andrea Camerini, Letizia Laera, Mariella Sorarù, Paolo Andrea Zucali, Valentina Guadalupi, Francesco Leonardi, Marcello Tiseo, Michele Tognetto, Francesco Di Costanzo, Carmine Pinto, Giorgia Negrini, Antonio Russo, Maria R. Migliorino, Marco Filetti, Sebastiano Buti

Research output: Contribution to journal › Article › peer-review

Abstract

Background Until now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs). Methods The prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety. Results The study enrolled 1279 patients; 1188 patients were evaluable for the primary endpoint analysis. Of them, 48.9% (581) received influenza vaccination. The overall ILI incidence was 8.2% (98 patients). Vaccinated patients were significantly more frequently elderly (p

Original language	English
Article number	e002619
Pages (from-to)	1-10
Number of pages	10
Journal	Journal for ImmunoTherapy of Cancer
Volume	9
Issue number	5
DOIs	https://doi.org/10.1136/jitc-2021-002619
Publication status	Published - May 2021

Keywords

antibodies
immunization
immunogenicity
immunotherapy
neoplasm
vaccination
vaccine

Access to Document

10.1136/jitc-2021-002619

Cite this

Bersanelli, M., Giannarelli, D., De Giorgi, U., Pignata, S., Di Maio, M., Clemente, A., Verzoni, E., Giusti, R., Di Napoli, M., Aprile, G., Ermacora, P., Catino, A., Scotti, V., Mazzoni, F., Guglielmini, P. F., Veccia, A., Maruzzo, M., Rossi, E., Grossi, F., ... Buti, S. (2021). INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2). Journal for ImmunoTherapy of Cancer, 9(5), 1-10. [e002619]. https://doi.org/10.1136/jitc-2021-002619

Bersanelli, M, Giannarelli, D , De Giorgi, U , Pignata, S, Di Maio, M, Clemente, A, Verzoni, E, Giusti, R, Di Napoli, M, Aprile, G, Ermacora, P, Catino, A, Scotti, V, Mazzoni, F, Guglielmini, PF, Veccia, A, Maruzzo, M, Rossi, E, Grossi, F , Casadei, C, Ficorella, C, Montesarchio, V, Verderame, F, Rizzo, M, Guaitoli, G, Fratino, L, Accettura, C, Mencoboni, M, Zustovich, F, Baldessari, C, Cinieri, S, Camerini, A, Laera, L, Sorarù, M, Zucali, PA, Guadalupi, V, Leonardi, F, Tiseo, M, Tognetto, M, Di Costanzo, F, Pinto, C, Negrini, G, Russo, A, Migliorino, MR, Filetti, M & Buti, S 2021, 'INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2).', Journal for ImmunoTherapy of Cancer, vol. 9, no. 5, e002619, pp. 1-10. https://doi.org/10.1136/jitc-2021-002619

@article{5201ea650cfe44338fb9007e97b8385d,

title = "INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2).",

abstract = "Background Until now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs). Methods The prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety. Results The study enrolled 1279 patients; 1188 patients were evaluable for the primary endpoint analysis. Of them, 48.9% (581) received influenza vaccination. The overall ILI incidence was 8.2% (98 patients). Vaccinated patients were significantly more frequently elderly (p",

keywords = "antibodies, immunization, immunogenicity, immunotherapy, neoplasm, vaccination, vaccine",

author = "Melissa Bersanelli and Diana Giannarelli and {De Giorgi}, Ugo and Sandro Pignata and {Di Maio}, Massimo and Alberto Clemente and Elena Verzoni and Raffaele Giusti and {Di Napoli}, Marilena and Giuseppe Aprile and Paola Ermacora and Annamaria Catino and Vieri Scotti and Francesca Mazzoni and Guglielmini, {Pamela Francesca} and Antonello Veccia and Marco Maruzzo and Ernesto Rossi and Francesco Grossi and Chiara Casadei and Corrado Ficorella and Vincenzo Montesarchio and Francesco Verderame and Mimma Rizzo and Giorgia Guaitoli and Lucia Fratino and Caterina Accettura and Manlio Mencoboni and Fable Zustovich and Cinzia Baldessari and Saverio Cinieri and Andrea Camerini and Letizia Laera and Mariella Sorar{\`u} and Zucali, {Paolo Andrea} and Valentina Guadalupi and Francesco Leonardi and Marcello Tiseo and Michele Tognetto and {Di Costanzo}, Francesco and Carmine Pinto and Giorgia Negrini and Antonio Russo and Migliorino, {Maria R.} and Marco Filetti and Sebastiano Buti",

year = "2021",

month = may,

doi = "10.1136/jitc-2021-002619",

language = "English",

volume = "9",

pages = "1--10",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "5",

}

TY - JOUR

T1 - INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2).

AU - Bersanelli, Melissa

AU - Giannarelli, Diana

AU - De Giorgi, Ugo

AU - Pignata, Sandro

AU - Di Maio, Massimo

AU - Clemente, Alberto

AU - Verzoni, Elena

AU - Giusti, Raffaele

AU - Di Napoli, Marilena

AU - Aprile, Giuseppe

AU - Ermacora, Paola

AU - Catino, Annamaria

AU - Scotti, Vieri

AU - Mazzoni, Francesca

AU - Guglielmini, Pamela Francesca

AU - Veccia, Antonello

AU - Maruzzo, Marco

AU - Rossi, Ernesto

AU - Grossi, Francesco

AU - Casadei, Chiara

AU - Ficorella, Corrado

AU - Montesarchio, Vincenzo

AU - Verderame, Francesco

AU - Rizzo, Mimma

AU - Guaitoli, Giorgia

AU - Fratino, Lucia

AU - Accettura, Caterina

AU - Mencoboni, Manlio

AU - Zustovich, Fable

AU - Baldessari, Cinzia

AU - Cinieri, Saverio

AU - Camerini, Andrea

AU - Laera, Letizia

AU - Sorarù, Mariella

AU - Zucali, Paolo Andrea

AU - Guadalupi, Valentina

AU - Leonardi, Francesco

AU - Tiseo, Marcello

AU - Tognetto, Michele

AU - Di Costanzo, Francesco

AU - Pinto, Carmine

AU - Negrini, Giorgia

AU - Russo, Antonio

AU - Migliorino, Maria R.

AU - Filetti, Marco

AU - Buti, Sebastiano

PY - 2021/5

Y1 - 2021/5

N2 - Background Until now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs). Methods The prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety. Results The study enrolled 1279 patients; 1188 patients were evaluable for the primary endpoint analysis. Of them, 48.9% (581) received influenza vaccination. The overall ILI incidence was 8.2% (98 patients). Vaccinated patients were significantly more frequently elderly (p

AB - Background Until now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs). Methods The prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety. Results The study enrolled 1279 patients; 1188 patients were evaluable for the primary endpoint analysis. Of them, 48.9% (581) received influenza vaccination. The overall ILI incidence was 8.2% (98 patients). Vaccinated patients were significantly more frequently elderly (p

KW - antibodies

KW - immunization

KW - immunogenicity

KW - immunotherapy

KW - neoplasm

KW - vaccination

KW - vaccine

U2 - 10.1136/jitc-2021-002619

DO - 10.1136/jitc-2021-002619

M3 - Article

SN - 2051-1426

VL - 9

SP - 1

EP - 10

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 5

M1 - e002619

ER -

INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2).

Abstract

Keywords

Access to Document

Fingerprint

Cite this